SDZ GLC 756Alternative Names: GLC 756
Latest Information Update: 12 Oct 2005
At a glance
- Originator Novartis
- Class Antiglaucomas
- Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 03 Oct 2000 Discontinued - Phase-I for Glaucoma in Switzerland (Ophthalmic)
- 12 Jun 1997 New profile
- 12 Jun 1997 Phase-I clinical trials for Glaucoma in Switzerland (Ophthalmic)